텍사스의 골수섬유증 임상 시험
골수섬유증 관련 연구 20개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.
텍사스의 도시
공식 연구 텍스트(영어)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Texas Oncology PA Dallas Presbyterian Hospital, Dallas
- MD Anderson Cancer Center, Houston
- SCRI Texas Oncology Northeast Texas, Tyler
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07357727A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- The University of Texas, MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Baylor University Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06343805High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT06345495A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Texas M. D. Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT07441694Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 15. 업데이트됨 · NCT07128381Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 26. 업데이트됨 · NCT06327100Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
피험자 모집 중1상
13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 20. 업데이트됨 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Md Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 17. 업데이트됨 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
피험자 모집 중2상
18세 ~ 66세 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06859424A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- MD Anderson, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 12. 업데이트됨 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UT - SouthWestern, Dallas
- U.T. MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at San Antonio, San Antonio
피험자 모집 중3상
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 4. 13. 업데이트됨 · NCT05423691Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2023. 2. 21. 업데이트됨 · NCT05280509ClinicalTrials.gov 출처, 2026. 10. 3. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.